UC San Diego is a renowned leader in medical research and innovation, consistently ranked among the top healthcare institutions worldwide. Our cutting-edge facilities, combined with a commitment to advancing cancer treatment, position us perfectly to offer novel, image-based prostate cancer therapies. UC San Diego’s Moores Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, exemplifies our dedication to delivering exceptional patient care and pioneering research. Our multidisciplinary team of experts in oncology, radiology, and medical imaging collaborates seamlessly to develop and implement groundbreaking treatments that leverage the latest advancements in technology. At UC San Diego, we pride ourselves on our robust research infrastructure and our ability to translate scientific discoveries into clinical applications swiftly. Our state-of-the-art imaging technologies, including advanced MRI and PET/CT systems, enable us to precisely target and treat prostate cancer with unparalleled accuracy. The institution’s extensive experience in clinical trials and our strong partnerships with leading biotech firms further enhance our capacity to bring innovative treatments from the lab to the clinic. This unique combination of expertise, advanced technology, and a patient-centered approach makes UC San Diego the ideal institution for offering novel, image-based prostate cancer treatments that promise to improve outcomes and quality of life for patients.
Urologic Oncologist
Aditya Bagrodia is an Associate Professor of Urology and genitourinary oncology disease team leader at UC San Diego. His practice is comprised of complex, multidisciplinary management all urologic malignancies. Dr. Bagrodia’s clinical and research focus centers on basic, translational, and clinical research for patients with genitourinary with an emphasis on prostate and testicular. He chairs the Eastern Cooperative Oncology Group testicular cancer working group and serves on the National Comprehensive Cancer Network testicular cancer guidelines. He is recognized as a leader and innovator in novel educational platforms, having co-created and hosting a podcast—Backtable Urology—a unique means to educate urology providers. Dr. Bagrodia volunteers his time and energy organizing patient-facing summits geared towards patients with prostate, bladder, testicular, and kidney cancers.
Urologic Oncologist
Juan Javier-DesLoges, MD, is a urologic oncologist who focuses on the management of prostate, bladder, kidney, and ureteral cancer. He specializes in robot-assisted minimally invasive surgery as well as transperineal procedures. Dr. Javier-DesLoges completed a fellowship in urologic oncology at UC San Diego School of Medicine and his residency in urology at Yale University. He obtained his medical degree from Rutgers New Jersey Medical School. He also holds a master’s degree from New York Medical College and completed his bachelor’s degree in biology from Boston College. Dr. DesLoges has expertise in all of urologic oncology, including robot-assisted radical cystectomy and urinary diversion, radical and partial nephrectomy, and radical prostatectomy. He also has a personal interest in alternatives to radical prostatectomy such as TULSA-PRO and high intensity frequency ultrasound in order to treat only cancerous tissue while preserving erectile function and urinary continence. As an assistant professor of urology at UC San Diego School of Medicine, he is involved in training medical students, residents and fellows. His research has been published in a variety of books and journals, including the Cancer, Journal of Urology, Urology, JAMA, and Urologic Oncology. He currently serves on the editorial board for the Journal of Urology. He is also a co-investigator on clinical trials and holds a certificate in clinical trial design and development.
Get the latest tips for all ages and stages. Subscribe to our newsletter.